[P3-106] A Study of CSF and Serum Neuronal biomarkers (Neuron Specific Enolase and S-100B protein) and Short Term Outcome in Children with Status Epilepticus
Prospectively, Serum and CSF samples of children with Status Epilepticus was analysed for neuron specific enolase (NSE) and S-100B protein. Clinical outcome was assessed by Pediatric cerebral performance scale. 938 children presented with seizures during study. 142 children met inclusion criteria; 102 excluded, 40 (29 boys) analysed. Serum and CSF-neuron specific enolase were found to be elevated in 28(70%) cases and 5(12%) cases respectively. While, serum-S-100B protein was found to be elevated in 31 (77%) cases whereas all except one case had normal CSF-S-100B protein levels. Out of 39 cases that were followed up 36 (92.5%) had good outcome. The good outcome group (n=36) had mean serum-NSE levels of 33.01±35.4 ng/ml whereas poor outcome group (n=3) had mean NSE levels of 48.4±69.2 ng/ml. The mean CSF-NSE levels in the good outcome group were 15.2±18 ng/ml and the poor outcome group had a mean NSE level value of 12.3±10.5 ng/ml. In the study the good outcome group (n=36) had mean serum-S100B levels of 485±487 pg/ml whereas poor outcome group (n=3) had mean S100B protein levels of 394±352 ng/ml. In mean CSF-S100B protein levels in the good outcome group is 168±287 pg/ml and the poor outcome group had mean S100B protein level values of 160±207 pg/ml. None of the above comparisons were statistically significant. Serum-NSE and S-100B protein are elevated in majority of children with status epilepticus. Preliminary trends suggest that mean serum values of NSE may be higher in children with poor outcome. CSF levels of these biomarkers were not informative.